nodgoРоссийский журнал детской гематологии и онкологии (РЖДГиО)Russian Journal of Pediatric Hematology and Oncology2311-12672413-5496LTD “Graphica”10.17650/2311-1267-2016-3-3-47-51nodgo-246Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ/ОБЗОРЫ ЛИТЕРАТУРЫORIGINAL INVESTIGATIONS/LITERATURE REVIEWSСовременные стратегии лечения острого миелоидного лейкозаModern strategies in AML treatmentРубнитцДж.Е.RubnitzJ.E.

Отдел онкологии, 

38105-2794, Теннесси, Мемфис, ул. Дэнни Томаса, 262

Department of Oncology, 

262 Danny Thomas Place, Memphis, TN 38105-2794

jeffrey.rubnitz@stjude.orgИсследовательский госпиталь Святого ИудыСоединённые Штаты АмерикиSt. Jude Children’s Research HospitalUnited States201622092016334751Copyright © Рубнитц Д., 20162016Рубнитц Д.Rubnitz J.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nodgo.org/jour/article/view/246

Острый миелоидный лейкоз (ОМЛ) – это комплексное заболевание, которое характеризуется широким спектром генетических и эпигенетических аномалий. Гетерогенность подтипов ОМЛ подразумевает, что улучшение клинических исходов требует разработки методов терапии, которые будут специфичными для каждого подтипа, и создания новых клинических исследований для подтверждения их целесообразности. В данном обзоре кратко представлены последние клинические исследования, генетическое разнообразие ОМЛ и мониторинг минимальной остаточной болезни.

Авторы перевода: К.И. Киргизов, Т.В. Шаманская

Acute myeloid leukemia (AML) is a complex disease that is characterized by diverse genetic and epigenetic abnormalities. The heterogeneity of AML subtypes implies that improvements in clinical outcome will require the development of therapies that are specific for each subtype of the disease and the design of novel clinical trials to test these strategies. In this review, we briefly summarize recent clinical trials, the genetic diversity of AML, and the use of minimal residual disease in the treatment of AML.

острый миелоидный лейкоздетилечениеминимальная остаточная болезньacute myeloid leukemiachildrentreatmentminimal residual diseaseReferencesZwaan C.M., Kolb E.A., Reinhardt D. et al. Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia. J Clin Oncol 2015;33:2949–62.Zwaan C.M., Kolb E.A., Reinhardt D. et al. Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia. J Clin Oncol 2015;33:2949–62.Creutzig U., Zimmermann M., Bourquin J.P. et al. Randomized trial comparing liposomal daunorubicin with idarubicin in induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004. Blood 2013;122:37–43.Creutzig U., Zimmermann M., Bourquin J.P. et al. Randomized trial comparing liposomal daunorubicin with idarubicin in induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004. Blood 2013;122:37–43.Gamis A.S., Alonzo T.A., Meshinchi S. et al. Gemtuzumab ozogamicin in children and adolescents with De Novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children's Oncology Group trial AAML0531. J Clin Oncol 2014;32:3021–32.Gamis A.S., Alonzo T.A., Meshinchi S. et al. Gemtuzumab ozogamicin in children and adolescents with De Novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children's Oncology Group trial AAML0531. J Clin Oncol 2014;32:3021–32.Gibson B.E., Webb D.K., Howman A.J. et al. Results of a randomized trial in children with Acute Myeloid Leukaemia: medical research council AML12 trial. Br J Haematol 2011;155:366–76.Gibson B.E., Webb D.K., Howman A.J. et al. Results of a randomized trial in children with Acute Myeloid Leukaemia: medical research council AML12 trial. Br J Haematol 2011;155:366–76.Rubnitz J.E., Inaba H., Dahl G. et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol 2010;11:543–52.Rubnitz J.E., Inaba H., Dahl G. et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol 2010;11:543–52.Dohner H., Weisdorf D.J., Bloomfield C.D. Acute Myeloid Leukemia. N Engl J Med 2015;373:1136–52.Dohner H., Weisdorf D.J., Bloomfield C.D. Acute Myeloid Leukemia. N Engl J Med 2015;373:1136–52.Grimwade D., Ivey A., Huntly B.J. Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. Blood 2016;127:29–41.Grimwade D., Ivey A., Huntly B.J. Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. Blood 2016;127:29–41.Papaemmanuil E., Gerstung M., Bullinger L. et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med 2016;374:2209–21.Papaemmanuil E., Gerstung M., Bullinger L. et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med 2016;374:2209–21.Rubnitz J.E., Inaba H. Childhood acute myeloid leukaemia. Br J Haematol 2012;159:259–76.Rubnitz J.E., Inaba H. Childhood acute myeloid leukaemia. Br J Haematol 2012;159:259–76.Klein K., Kaspers G., Harrison C.J. et al. Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Munster Study Group. J Clin Oncol 2015;33:4247–58.Klein K., Kaspers G., Harrison C.J. et al. Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Munster Study Group. J Clin Oncol 2015;33:4247–58.Balgobind B.V., Raimondi S.C., Harbott J. et al. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood 2009;114:2489–96.Balgobind B.V., Raimondi S.C., Harbott J. et al. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood 2009;114:2489–96.Tierens A., Bjorklund E., Siitonen S. et al. Residual disease detected by flow cytometry is an independent predictor of survival in childhood acute myeloid leukaemia; results of the NOPHO-AML 2004 study. Br J Haematol 2016; 174:600–9.Tierens A., Bjorklund E., Siitonen S. et al. Residual disease detected by flow cytometry is an independent predictor of survival in childhood acute myeloid leukaemia; results of the NOPHO-AML 2004 study. Br J Haematol 2016; 174:600–9.Ivey A., Hills R.K., Simpson M.A. et al. Assessment of Minimal Residual Disease in Standard-Risk AML. N Engl J Med 2016;374:422–33.Ivey A., Hills R.K., Simpson M.A. et al. Assessment of Minimal Residual Disease in Standard-Risk AML. N Engl J Med 2016;374:422–33.Klco J.M., Miller C.A., Griffith M. et al. Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia. J Am Med Assoc 2015;314:811–22.Klco J.M., Miller C.A., Griffith M. et al. Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia. J Am Med Assoc 2015;314:811–22.Cornelissen J.J., Blaise D. Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood 2016;127:62–70.Cornelissen J.J., Blaise D. Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood 2016;127:62–70.Stein E.M., Tallman M.S. Emerging therapeutic drugs for AML. Blood 2016;127:71–8.Stein E.M., Tallman M.S. Emerging therapeutic drugs for AML. Blood 2016;127:71–8.Wouters B.J., Delwel R. Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia. Blood 2016;127:42–52.Wouters B.J., Delwel R. Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia. Blood 2016;127:42–52.

The authors declare that there are no conflicts of interest present.